Venetoclax-Obenituzumab-Fixed-Based Approaches for CLL

Venetoclax-obenituzumab and the triplet regimen MRD-negative states in the peripheral blood after a one-year of therapy upwards of close to 85 to 90 percent. And so it looks really, really good. This study I think has confirmed final and foremost that Rutuxumab is an inferior antibody in CLL. But what we're seeing here though is who is going to progress sooner. So they're still in treatment, great regimen, very safe regimen, and also is providing great evidence of and setting new benchmarks for what to expect going forward.